FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, ...
ctDNA detection has advanced, allowing identification of minimal residual disease and predicting cancer recurrence with high sensitivity. Liquid biopsies offer a minimally invasive method to analyze ...
(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring SAGA Diagnostics, a pioneer in blood-based ...
Please provide your email address to receive an email when new articles are posted on . Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS.
Minimal residual disease (MRD) is a term referring to the small populations of cancer cells that may remain in the body following primary treatment. Early and accurate MRD detection is important for ...
The MarketWatch News Department was not involved in the creation of this content. Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, ...
News-Medical.Net on MSN
Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results